Trial offers early test case for personalized medicine.
Garber
Ken
K
D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001549:Benzamides / Q000494:pharmacology / Q000627:therapeutic use; D001562:Benzimidazoles / Q000494:pharmacology / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D002986:Clinical Trials as Topic / Q000379:methods*; D004159:Diphenylamine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D017277:Drug Approval; D066246:ErbB Receptors / Q000187:drug effects / Q000378:metabolism; D005260:Female; D006801:Humans; D009154:Mutation; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D048493:Proto-Oncogene Proteins B-raf / Q000187:drug effects / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000187:drug effects / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D000068878:Trastuzumab; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001549:Benzamides; D001562:Benzimidazoles; D014408:Biomarkers, Tumor; D004159:Diphenylamine; D066246:ErbB Receptors; D048493:Proto-Oncogene Proteins B-raf; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C517975:AZD 6244; C506614:mirdametinib; C482119:BRAF protein, human